Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.73
+0.26 (0.95%)
Mar 9, 2026, 1:19 PM EDT - Market open
Agios Pharmaceuticals Employees
As of December 31, 2025, Agios Pharmaceuticals had 540 total employees, including 539 full-time and 1 part-time employees. The number of employees increased by 52 or 10.66% compared to the previous year.
Employees
540
Change (1Y)
52
Growth (1Y)
10.66%
Revenue / Employee
$100,052
Profits / Employee
-$764,409
Market Cap
1.62B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 952 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Nuvation Bio | 291 |
| Innoviva | 159 |
| AnaptysBio | 136 |
| Nanobiotix | 103 |
AGIO News
- 7 days ago - Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - GlobeNewsWire
- 24 days ago - Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewsWire
- 7 weeks ago - Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - GlobeNewsWire
- 2 months ago - Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - GlobeNewsWire
- 2 months ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript - Seeking Alpha